首页> 外文期刊>Allergy, Asthma & Immunology Research >Decreased CRTH2 Expression and Response to Allergen Re-stimulation on Innate Lymphoid Cells in Patients With Allergen-Specific Immunotherapy
【24h】

Decreased CRTH2 Expression and Response to Allergen Re-stimulation on Innate Lymphoid Cells in Patients With Allergen-Specific Immunotherapy

机译:过敏原特异性免疫治疗患者的固有淋巴细胞CRTH2表达降低和对过敏原再刺激的反应

获取原文
       

摘要

Purpose Group 2 innate lymphoid cells (ILC2s) have been implicated in the pathogenesis of allergic disease. However, the effect of allergen-specific immunotherapy (AIT) on ILCs remains to be clarified. The aim of this study was to evaluate the levels of ILC subsets in allergic rhinitis (AR) patients in response to house dust mite (HDM)-specific immunotherapy. Methods We enrolled 37 AR patients undergoing AIT (16 responders and 11 non-responders) for 2 years, 35 HDM AR patients and 28 healthy subjects. Peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry to identify ILC subsets. Stimulation of ILC2s with recombinant allergen-specific protein was used to determine ILC2's activation (CD69 expression). Results Responder AIT patients and healthy subjects had a decreased frequency of circulating ILC2s compared to non-responder AIT and AR patients. Conversely, ILC1s from responder AIT patients and healthy subjects showed increased frequency compared to non-responder AIT and AR patients. The frequency of ILC3s natural cytotoxicity receptor (NCR)+ and NCR? in responder AIT patients was significantly lower compared to AR patients and healthy subjects. The ILC1: ILC2 proportion in responder AIT patients was similar to that of healthy subjects. PBMCs from patients who were responders to AIT had a significantly lower expression of the activation marker CD69 on ILC2s in response to allergen re-stimulation compared to AR patients, but no difference compared to non-responder AIT patients and healthy subjects. Conclusions We propose that AIT might affect ILC responses. The activation of ILC2s was reduced in AR patients treated with AIT. Our results indicate that a relative ILC1/ILC2 skewed response is a possible key to successful AIT.
机译:目的第2组先天性淋巴样细胞(ILC2s)与过敏性疾病的发病机制有关。但是,变应原特异性免疫疗法(AIT)对ILC的作用仍有待阐明。这项研究的目的是评估过敏性鼻炎(AR)患者对屋尘螨(HDM)特异性免疫疗法的反应中ILC亚群的水平。方法我们招募了37名接受AIT治疗2年的AR患者(16名有反应者和11名无反应者),35名HDM AR患者和28名健康受试者。通过流式细胞术分析外周血单核细胞(PBMC)以鉴定ILC亚群。用重组变应原特异性蛋白刺激ILC2,以确定ILC2的激活(CD69表达)。结果与无反应者AIT和AR患者相比,反应者AIT患者和健康受试者的循环ILC2频率降低。相反,与无反应者AIT和AR患者相比,有反应者AIT患者和健康受试者的ILC1频率增加。 ILC3s天然细胞毒性受体(NCR)+和NCR的频率?与AR患者和健康受试者相比,有反应的AIT患者中的患者明显降低。应答性AIT患者中的ILC1:ILC2比例与健康受试者相似。与AR患者相比,对AIT有反应的患者的PBMC在响应变应原刺激时ILC2s上活化标记CD69的表达明显降低,但与无反应的AIT患者和健康受试者相比,无差异。结论我们建议AIT可能会影响ILC反应。 AIT治疗的AR患者中ILC2s的激活减少。我们的结果表明,相对的ILC1 / ILC2偏斜响应是成功进行AIT的可能关键。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号